Lyell Immunopharma, Inc. (LYEL)
NASDAQ: LYEL · Real-Time Price · USD
21.48
-1.14 (-5.06%)
At close: Apr 28, 2026, 4:00 PM EDT
21.49
+0.01 (0.07%)
After-hours: Apr 28, 2026, 4:04 PM EDT
Lyell Immunopharma Stock Forecast
Stock Price Forecast
The 5 analysts with 12-month price forecasts for Lyell Immunopharma stock have an average target of 30.6, with a low estimate of 10 and a high estimate of 45. The average target predicts an increase of 42.49% from the current stock price of 21.48.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Lyell Immunopharma stock from 5 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 2 | 2 | 2 | 2 | 3 |
| Buy | 0 | 0 | 0 | 0 | 1 | 1 |
| Hold | 2 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 3 | 3 | 3 | 3 | 4 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Needham | Needham | Strong Buy Initiates $44 | Strong Buy | Initiates | $44 | +104.89% | Apr 10, 2026 |
| Citizens | Citizens | Buy Initiates $34 | Buy | Initiates | $34 | +58.32% | Mar 9, 2026 |
| HC Wainwright & Co. | HC Wainwright & Co. | Hold → Strong Buy Upgrades $20 → $45 | Hold → Strong Buy | Upgrades | $20 → $45 | +109.55% | Dec 9, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Hold Maintains $10 → $20 | Hold | Maintains | $10 → $20 | -6.87% | Nov 24, 2025 |
| LUCID CAPITAL MARKETS | LUCID CAPITAL MARKETS | Strong Buy Initiates $20 | Strong Buy | Initiates | $20 | -6.87% | Sep 26, 2025 |
Financial Forecast
Revenue This Year
17.54K
from 36.00K
Decreased by -51.27%
Revenue Next Year
1.55M
from 17.54K
Increased by 8,712.13%
EPS This Year
-9.90
from -16.06
EPS Next Year
-9.48
from -9.90
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 48,300 | 7.9M | ||||||
| Avg | 17,544 | 1.5M | ||||||
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 34.2% | 44,787.1% | ||||||
| Avg | -51.3% | 8,712.1% | ||||||
| Low | - | - |
EPS Forecast
| EPS | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | -9.10 | -8.64 | |
| Avg | -9.90 | -9.48 | |
| Low | -11.04 | -11.46 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | - | - | |
| Avg | - | - | |
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.